Antiviral Efficacy and Mechanism of BD-77 Against Novel Coronavirus SARS-CoV-2
10.13422/j.cnki.syfjx.20240102
- VernacularTitle:BD-77抑制新型冠状病毒SARS-CoV-2药效及机制探讨
- Author:
Lei BAO
1
;
Qinhai MA
2
;
Shanshan GUO
1
;
Ronghua ZHAO
1
;
Wen XIA
3
;
Zihan GENG
1
;
Jing SUN
1
;
Yanyan BAO
1
;
Zhou XU
4
;
Shenglong YAN
3
;
Jinxin XIAO
3
;
Huarong CHEN
3
;
Chenggang HUANG
4
;
Xiaolan CUI
1
Author Information
1. Institute of Chinese Materia Medica，China Academy of Chinese Medical Sciences，Beijing 100700，China
2. Guangzhou Medical University，Guangzhou 511495，China
3. Medical Sciences Guizhou Bailing Enterprise Group Pharmaceutical Co. Ltd.，Anhun 561099，China
4. Shanghai Institute of Materia Medica，Chinese Academy of Sciences，Shanghai 201203，China
- Publication Type:Journal Article
- Keywords:
novel coronavirus SARS-CoV-2;
BD-77;
human angiotensin converting enzyme2 （hACE2） transgenic mouse model;
Delta variant strain;
Omicron variant strain
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2024;30(13):45-51
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveThe human angiotensin converting enzyme2 （hACE2） transgenic mouse model was used to clarify the antiviral efficacy of BD-77 against a novel coronavirus SARS-CoV-2 and explore the action mechanism of BD-77 against SARS-CoV-2. MethodSARS-CoV-2 Omicron and Delta variant strains-infected VeroE6 cell models were established and administered with BD-77 to observe the antiviral effect of BD-77 in vitro. A kit was used to detect the effect of BD-77 in vitro on the binding of spike S protein of SARS-CoV-2 virus （Delta/Omicron） to angiotensin converting enzyme2 （ACE2）. Chromatography was adopted to detect the binding of BD-77 to the S protein and N protein of the novel coronavirus. hACE2 transgenic C57BL/6 mice were divided into a blank control group， SARS-CoV-2 infection group， BD-77 administration groups of 37.5 mg·kg-1 and 75 mg·kg-1， with eight mice in each group. The pneumonia model of SARS-CoV-2-infected hACE2 transgenic mice was built to observe the survival of the mice， detect the virus titer of the lung tissue of the mice， and observe the lesions in the lung tissue. ResultBD-77 had a certain inhibitory effect on Omicron and Delta variant strains in vitro， with median inhibitory concentration （IC50） of 526.3 mg·L-1 and 653.0 mg·L-1， respectively. BD-77 had no significant inhibitory effect on the binding of the S protein of WT， Omicron， and Delta variant strains of SARS-CoV-2 to ACE2 and had no binding effect with the S protein and N protein of the novel coronavirus. No mice in the blank group died， while the mortality rate of SARS-CoV-2-infected mice was 75%. There was a large amount of virus replication in the lung tissue of the mice and large areas of inflammatory infiltration in the lung tissue and interstitium. Compared with the model group， BD-77 administration groups of 37.5 mg·kg-1 and 75 mg·kg-1 could reduce the mortality of mice， significantly lower the virus titer in the lung tissue of mice （P<0.05）， and improve lung lesions. ConclusionBD-77 demonstrated significant inhibitory effects against SARS-CoV-2 virus in vitro and in vivo. However， its mechanism of action did not involve direct inhibition of the virus itself or intervention in the virus-host binding process. This finding suggests that the mechanism of action of BD-77 needs to be thoroughly investigated and elucidated by further experiments.
